FindTrial
Sign In

MRTX849

DRUG10 trials

Sponsors

Mirati Therapeutics Inc., Zai Lab (Shanghai) Co., Ltd., M.D. Anderson Cancer Center

Conditions

Advanced CancerAdvanced Colorectal CancerAdvanced Non Small Cell Lung CancerAdvanced Solid TumorAdvanced or Metastatic Solid TumorColo-rectal CancerColon CancerColorectal Cancer

Phase 1

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Active, not recruitingNCT03785249
Mirati Therapeutics Inc.Advanced Cancer, Malignant Neoplastic Disease, Metastatic Cancer
Start: 2019-01-15End: 2026-12-31Updated: 2025-09-30
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
CompletedNCT04330664
Mirati Therapeutics Inc.Advanced Cancer, Malignant Neoplastic Disease, Metastatic Cancer
Start: 2020-04-07End: 2025-02-24Updated: 2025-04-04
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
TerminatedNCT04975256
Mirati Therapeutics Inc.Advanced Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung +2
Start: 2021-07-28End: 2022-11-15Updated: 2024-12-16
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
CompletedNCT05178888
Mirati Therapeutics Inc.Advanced Solid Tumor
Start: 2022-01-20End: 2024-12-30Updated: 2025-02-11
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
NCT05263986
Zai Lab (Shanghai) Co., Ltd.Advanced or Metastatic Solid Tumor
Start: 2022-05-30End: 2023-10-31Updated: 2023-02-27
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
TerminatedNCT05578092
Mirati Therapeutics Inc.Advanced Solid Tumor, Colo-rectal Cancer, Non Small Cell Lung Cancer +1
Start: 2022-12-02End: 2026-02-03Updated: 2026-02-19
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
WithdrawnNCT05634525
M.D. Anderson Cancer CenterMetastatic Pancreatic Cancer
Start: 2023-05-03End: 2025-07-21Updated: 2025-07-25
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
Active, not recruitingNCT05722327
M.D. Anderson Cancer CenterColon Cancer, Colorectal Cancer
Start: 2023-12-06End: 2027-09-30Target: 24Updated: 2026-03-04

Phase 3

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Active, not recruitingNCT04685135
Mirati Therapeutics Inc.Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Start: 2021-02-23End: 2026-07-02Updated: 2025-01-22
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Active, not recruitingNCT04793958
Mirati Therapeutics Inc.Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Start: 2021-06-24End: 2026-01-30Updated: 2025-02-11

Related Papers

Adagrasib versus docetaxel in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
2025-08-014 citations
Ethnic disparities in clinical trials for FDA-approved drugs in lung cancer: A post-COVID era analysis (2020-2024).
Journal of Clinical Oncology2025-05-28
Ethnic disparities in clinical trials for FDA-approved drugs in colon cancer: A post-COVID era analysis (2020-2024).
Journal of Clinical Oncology2025-05-28
Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring <i>KRAS</i>G12Cand <i>STK11</i> mutations: KRYSTAL-1 phase 2 cohort
Cancer Research2025-04-25
Adagrasib (Ada) + cetuximab (Cetux) for <i>KRAS</i> <sup>G12C</sup> -mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.
Journal of Clinical Oncology2025-01-272 citations
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Clinical Cancer Research2025-01-1314 citations
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS<sup>G12C</sup> mutation.
Journal of Clinical Oncology2024-06-0563 citations
Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC
Cancer Research2024-03-221 citations
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS<sup>G12C</sup></i>-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
Journal of Clinical Oncology2023-06-1656 citations
Adagrasib in Advanced Solid Tumors Harboring a<i>KRAS</i><sup><i>G12C</i></sup>Mutation
Journal of Clinical Oncology2023-04-26240 citations
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRAS<sup>G12C</sup> mutation.
Journal of Clinical Oncology2023-04-2030 citations
FDA Accelerated Approval of Adagrasib for Non-Small Cell Lung Cancer
Oncology Times2023-02-20
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C
New England Journal of Medicine2022-12-21432 citations
LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Immuno-Oncology Technology2022-12-0140 citations
Adagrasib: A landmark in the KRAS<sup>G12C</sup>‐mutated NSCLC
MedComm2022-11-2511 citations
Abstract CT242: KRYSTAL-16: A phase I/Ib trial of adagrasib (MRTX849) in combination with palbociclib in patients with advanced solid tumors with KRASG12C mutation
Cancer Research2022-06-153 citations
Activity of adagrasib (MRTX849) in patients with KRAS<sup>G12C</sup>-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.
Journal of Clinical Oncology2022-06-0826 citations
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
New England Journal of Medicine2022-06-03875 citations
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRAS<sup>G12C</sup> mutation.
Journal of Clinical Oncology2022-06-0141 citations
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS<sup>G12C</sup> mutation.
Journal of Clinical Oncology2022-01-1977 citations

6 more papers not shown